MedTrace Logo

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

NCT06520540 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-07-25

No results posted yet for this study

Summary

• To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.

Conditions

  • Glucagon-Like Peptide-1 Receptor Agonists

Interventions

DRUG

HDM1002 100 mg QD 12weeks

Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)

DRUG

HDM1002 200 mg QD 12weeks

Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)

DRUG

HDM1002 400 mg QD 12weeks，Q 2W for titration

Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration

DRUG

HDM1002 400 mg QD 12weeks，Q 3W for titration

Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration

DEVICE

Placebo

Placebo

Sponsors & Collaborators

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaoying Li · Zhongshan Hospital, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-28
Primary Completion
2024-11-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06520540 on ClinicalTrials.gov